drugset / Trial / NCT05082714
Tocilizumab Versus Baricitinib in Patients With Severe COVID-19
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to investigate whether baricitinib is non-inferior to tocilizumab in severe COVID-19.
Timeline
- Start
- 2021-10-20
- Primary completion
- 2022-06-04
- Completion
- 2022-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 2 mg | — |
| Subject | Baricitinib | Small molecule | 4 mg | — |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | — |